CD8A and neoplasm: In this study, we developed neoantigen prediction workflows, VACINUSpMHC and VACINUSTCR, based on the neoepitope presentation on the patient’s MHC class I molecules and the interaction between the patient’s putative tumor-reactive CD8+ TIL TCR and neoepitope-MHC recognition, respectively, and validated the predicted neoantigens in vitro and in vivo.